Ajanta Pharma, Biocon Partner for Semaglutide Marketing in 26 Countries

• Ajanta Pharma signed an in-licensing agreement with Biocon for exclusive and semi-exclusive marketing of semaglutide in 26 countries.
• Biocon will supply semaglutide, a GLP-1 receptor agonist for glycaemic control, across Africa, the Middle East, and Central Asia.
• The product patent expires in most markets by March 2026; commercialization is expected by Ajanta Pharma in late 2026 or early 2027.
• Ajanta Pharma MD Yogesh Agrawal and Biocon CEO Siddharth Mittal highlighted the strategic importance and market potential of the partnership.
• Ajanta Pharma shares fell 1.14%, while Biocon shares rose 0.4% on the day of the announcement.

Why It Matters: Ajanta Pharma and Biocon collaborate to expand semaglutide's global reach, targeting 26 countries.